Bakri SJ, Risco M, Edwards AO et al.
Mayo Clinic, Rochester, MN, USA.
Am J Ophthalmol 2009;148:66–9.
Editor’s note: This is a retrospective case-series of 35 eyes receiving bilateral simultaneous intravitreal injections in an office setting. The indications for injection were choroidal neovascularization secondary to age-related macular degeneration (49 eyes), diabetic macular edema (13 eyes), proliferative diabetic retinopathy (four eyes), macular edema secondary to retinal vein occlusion (two eyes), and macular edema secondary to autoimmune retinopathy (two eyes). The agents injected were bevacizumab, bevacizumab plus triamcinolone, ranibizumab, and bevacizumab plus dexamethasone.